Role of platelet activating factor in cardiac dysfunction, apoptosis and nitric oxide synthase mRNA expression in the ischemic-reperfused rabbit heart

Canadian Journal of Cardiology

Volumn 19, Issue 3, 2003, Pages 267-274

  Loucks, Erick B ^b   Godin, David V ^b   Walley, Keith R ^b   McManus, Bruce M ^b   Rahimian, Roshanak ^b   Grantville, David J ^b   Hong, Jong Myeon ^a   Aktary, Fatma M ^a   Qayumi, A Karim ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Apoptosis; Ischemia; Nitric oxide; Reperfusion injury

Indexed keywords

3 BROMO 5 [N PHENYL N [2 [[2 (1,2,3,4 TETRAHYDRO 2 ISOQUINOLYLCARBONYLOXY)ETHYL]CARBAMOYL]ETHYL]CARBAMOYL] 1 PROPYLPYRIDINIUM NITRATE; DRUG VEHICLE; MESSENGER RNA; NITRIC OXIDE SYNTHASE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; DNA FRAGMENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOQUINOLINE DERIVATIVE; PYRIDINIUM DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; FEMALE; HEART DISEASE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; ISOLATED HEART; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RABBIT; REPERFUSION INJURY; VASOCONSTRICTION; ANIMAL; CORONARY ARTERY BLOOD FLOW; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION; GENETICS; HEART CONTRACTION; IN VITRO STUDY; METABOLISM; PATHOPHYSIOLOGY; TIME; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CORONARY CIRCULATION; DNA FRAGMENTATION; GENE EXPRESSION; ISOQUINOLINES; MYOCARDIAL CONTRACTION; MYOCARDIAL REPERFUSION INJURY; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION INHIBITORS; PYRIDINIUM COMPOUNDS; RABBITS; RNA, MESSENGER; TETRAHYDROISOQUINOLINES; TIME FACTORS;

EID: 0037444902     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Fibrinolytic Therapy Trialists' (FTT) COllaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
2. Alloatti G, Penna C De Martino A, Montrucchio G, Camussi R. Role of nitric oxide and platelet-activating factor in cardiac alterations induced by tumor necrosis factor-alpha in the guinea-pig papillary muscle. Cardiovasc Res 1999;41:611-9.
3. Bonavida B, Mencia-Huerta JM, Braquet P. Effect of platelet-activating factor on monocyte activation and production of tumor necrosis factor. Int Arch Allergy Appl Immunol 1989;88:157-60.
4. Forstermann U. Regulation of nitric oxide synthase expression and activity. In: Mayer B, ed. Handbook of Experimental Pharmacology. New York: Springer-Verlag, 2000:71-91.
5. Lamontagne D, Pohl U, Busse R. Mechanical deformation of vessel wall and shear stress determine the basal relese of endothelium-derived relaxing factor in the intacgt rabbit coronary vascular bed. Circ Res 1992; 70: 123-30.
6. Liao JK, Shih WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem. 1995;270:319-24.
7. Szabo C, Wu CC, Mitchell JA, Gross SS, Thiermermann C, Vane JR. Platelet-activating factor contributes to the induction of nitric oxide synathase by bacterial lipopolysaccharide. Circ Res 1993; 73:991-9.
8. Katoh S, Toyama J, Kodama I, Koike A, Abe T. Role of platelet activating factor in ischaemia-reperfusion injury of isolated rabbit hearts: Protective effect of a specific platelet activating factor antagonist, TCV-309. Cardiovasc Res 1993; 55: 504-15.
9. Ko W, Lang D, Hawes AS, Zelano JA, Isom OW, Krieger KH. Pletelet-activating factor antagonism attenuates platelet and neurotrophil activation and reduces myocardial injury during coronary reperfusion. J Surg REs 1993;55:504-15.
10. Maruyama M, Farber NE, Vercellotti G M, Jacob HS, Gross GJ. Evidence for a role of platelet activating factor in the pathogenesis of irreversible but not reversible myocardial injury after reperfusion in dogs. Am Heart J 1990; 120:510-20.
11. Montrucchio G, Alloatti G, Mariano F, et al. Role of platelet-activating factor in the reperfusion injury of rabbit ischemic heart. Am J Pathol 1990;137:71-83.
12. Ioculano M, Squadrito F, Altavilla D, et al. Protective effects of L-659,989, a platelet-activating factor receptor antagonist, in myocardial ischemia and reperfusion in rats. J Cardiovasc Pharmacol 1994;23:7-12.
13. Loucks EB, Qayumi AK, Godin DV, et al. Therapeutic potential of platelet-activating factor antagonism in the management of myocardial infarction. Can J Cardiol 2000;16:497-504.
14. Schrodeer E, Pouleur H, Van Mechelen H, Keyeux A, Raigoso J, Charlier A. Alterations in endocardial vascular resistance after reperfusion in a low flow, high demand model of ischemia: Effects of dipyridamole and WEB-2086, a platelet-activating factor antagonist. J Am Coll Cardiol 1990;16:1750-9.
15. Koltai M, Tosaki A, Hosford D, Braquet P. Ginkgolide B Protects isolated hearts against arrhythmias induced by ischemia but not reperfusion. Eur J Pharmacol 1989;164:293-302.
16. Liu P, Hock CE, Nagele R, Wong PY. Formation of nitric oxide, superoxide, and peroxynitrite in myocardial ischemia-reperfusion injury in rats. Am J Physiol 1997;272:H2327-36.
17. Wildhirt SM, Weismueller S, Schulze C, Conrad N, Kornberg A, Reichard B. Inducible nitric oxide synthase activation after ischemia/reperfusion contributes to myocardial dysfunction and extent of infarct size in rabbits: Evidence for a late phase of nitric oxide-mediated reperfusion injury. Cardiovasc Res 1999;43:698-711.
18. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994;94:1621-8.
19. Holly TA,Drincic A, Byun Y, et al. Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J Mol Cell Cardiol 1999;31:1709-15.
20. Scarabelli T, Stephanou A, Rayment N, et al. Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury. Circulation 2001;104:253-6.
21. Man XL, Kumar S, Gao F, et al. Inhibition of p38 mitogen-activted protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 1999;99:1685-91.
22. Goddard CM, Allard MF, Hogg JC, Walley KR. Myocardial morphometric changes related to decreased contractility after endotoxin. Am J Physiol 1996;270:H1446-52.
23. Parrino, PE, Laubach VE, Gaughen JR Jr, et al. Inhibition of inducible nitric oxide synthase after myocardial ischemia increases coronary flow. Ann Thorac Surg 1988;66:733-9.
24. Rahimian R, Masih-Khan E, Lo M, Van Breemen C, McManus BM, Dubé GP. Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus. Mol Cell Biochem 2001:224;29-37.
25. Granville DJ, Carthy CM, Hunt DW, McManus BM. Apoptosis: Molecular aspects of cell death and disease. Lab Invest 1998;78:893-913.
26. Nikbakht-Sangari M, Qayumi AK, Keown P, Durunio V, Horley K. Platelet-activating factor plays a role in gthe mechanism of major histocompatibility complex in T lymphocytes. Immunol Invest 1999;28:223-33.
27. Ma XL, Weyrich AS, Kratnz S, Lefer AM. Mechanisms of the cardioprotective actions of WEB-2170, bepafant, a platelet activating factor antagonist, an myocardial ischemia and reperfusion. J Pharmacol Exp Ther 1992;260:1229-36.
28. Delgado R, Rojas A, Glaria LA, et al. Ca(2)-independent nitric oxide synthase activity in human lung after cardiopulmonary bypass. Thorax 1995;50:403-4.
29. Yaoita H, Ogawa K, Maehara K, Maruyama Y. Apoptosis in relevant clinical situations: Contribution of apoptosis in myocardial infarction. Cardiovasc Res 2000;45:630-41.
30. Kajstura J, Cheng W, Reiss K, et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 1996;74;86-107.
31. Galle J, Schneider R, Heinloth A, et al. Lp(a) and LDL induce apoptosis in human endothelial cells and rabbit aorta: Role of oxidatiove stress. Kidney Int 1999;55:1450-61.
32. Dimmerler S, Hermann C, Galle J, Zeiher AM. Upregulation of superoxide dismutase and nitric oxide synthase mediates the apoptosis-suppressive effects of shear stress on endothelial cells. Arterioscler Thromb Vasc Biol 1999;19:656-64.
33. Dimmeler S, Zeiher AM. Nitric oxide-an endothelial cell survival factor. Cell Death Differ 1999;6:964-8.
34. Yaoita H, Ogawa K, Maehara K, Maruyama Y. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 1998;97:276-81.
35. Okamura T, Miura T, Takemura G, et al. Effect of caspase inhibitors on myocardial infarct size and myocyte DNA fragmentation in the ischemia-reperfused rat heart. Cardiovasc Res 2000;45:642-50.